PT
Autoridade da Concorrência

Case details

Print
Merger control
Case reference
CCENT/2009/27 - REF IV Associates / CRIOESTAMINAL
Acquired
Crioestaminal
Description
a Portuguese-based undertaking that provides collection and cryopreservation services for umbilical cord blood stem cells.
Acquiring
Riverside
Description
an investment fund with its headquarters in the Cayman Islands; it belongs to the "Riverside" private equity group, which specialises in purchasing and cooperating in the management of small and medium-sized enterprises, on a world scale;
Sector
  • Health & Pharmaceutical
  • Liberal Professions
Activity (NACE)
  • M72 - Scientific research and development
  • Q86 - Human health activities
Applicable legislation
Art. 9(1)(a) (Law 18)
Notification thresholds
Market share
Type of merger
Conglomerate
Cooperation with sector regulators
Status
Closed
Type of Investigation
Phase 1
AdC’s decision
Non-opposition
Case description
Notified on 28 July 2009, this merger operation consists of the acquisition, by the investment fund REF IV Associates Cayman LP (henceforth "REF IV Associates"), via the special purpose entity REF IV Luxembourg S.à.r.l., of exclusive control of the undertaking Crioestaminal - Saúde e Tecnologia SA (henceforth "Crioestaminal") and its subsidiaries.
Timeline
2009-09-03
COMPETITION AUTHORITY authorises Merger No. 27/2009 - REF IV Associates (Riverside)/CRIOESTAMINAL
2009-08-06
Publication of the announcement
Click here to see your activities